FDA’s Opdivo Lung Cancer Approval

By João L. Carapinha

October 11, 2024

The FDA has approved a new treatment regimen using Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC), marking a significant advancement in cancer care. This approval paves the way for adult patients with resectable NSCLC to receive a combination of Opdivo and platinum-doublet chemotherapy as a neoadjuvant therapy, followed by surgery, and then adjuvant single-agent Opdivo. This targeted approach is for patients who do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) rearrangements.

Approval Details

The FDA has approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by surgery, and then adjuvant single-agent Opdivo for adult patients with resectable NSCLC. This approval specifically targets patients without EGFR or ALK rearrangements.

Clinical Trial

The approval is based on the results of the Phase III CheckMate-77T trial, a randomized, double-blind, multi-center study. The trial involved 461 patients and compared neoadjuvant Opdivo with platinum-doublet chemotherapy followed by surgery and adjuvant single-agent Opdivo against neoadjuvant platinum-doublet chemotherapy and placebo followed by surgery and adjuvant placebo.

Efficacy

Results demonstrated that the combination of Opdivo with chemotherapy significantly enhanced event-free survival (EFS) and pathologic complete response (pCR) compared to chemotherapy alone. Notably, the median EFS was not reached in the nivolumab arm, while it stood at 18.4 months in the chemotherapy arm (HR, 0.58; 95% CI, 0.43-0.78; P = 0.00025).

Safety

Adverse events (AEs) were comparable to those seen in previous clinical trials involving nivolumab and chemotherapy. A small portion of patients treated with nivolumab experienced delays in surgery or were unable to undergo the procedure due to AEs.

Clinical Implications

This FDA approval represents a critical step in addressing the treatment needs of patients requiring therapies before and after surgery to target micrometastasis, lower the risk of cancer recurrence, and enhance surgical success. This regimen holds promise for improved EFS and may lead to a pCR in one out of four patients.

Expanded Role of Opdivo

The FDA’s decision expands the role of Opdivo-based treatments, building upon prior approvals for neoadjuvant-only Opdivo plus chemotherapy for resectable NSCLC, as demonstrated in the CheckMate-816 trial. This reinforces Bristol Myers Squibb’s commitment to enhancing patient outcomes and broadening its thoracic portfolio in early-stage diseases, with Opdivo now playing a pivotal role in treatment protocols for resectable NSCLC.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...